{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:56:31Z","timestamp":1793876191568,"version":"4.7.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Science, Technology & Innovation Funding Authority"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polyethylene glycol loxenatide (PEX168) is a novel glucagon-like peptide-1 receptor agonist with a longer half-life developed by modifying the chemical structure of exenatide. This study aims to assess the efficacy and safety of PEX168 and determine the best dose. We searched PubMed, Scopus, Cochrane Library, and Web of Science\u00a0databases from inception to April 25, 2023, for randomized controlled trials (RCTs) comparing PEX168 therapy alone or in combination with metformin versus other therapies. We used the risk ratio (RR) for dichotomous outcomes and the mean difference (MD) for continuous outcomes, both with 95% confidence intervals (CI). Six RCTs, including 1248 participants, were included. PEX168 added to metformin was significantly better than metformin alone regarding fasting blood glucose (MD\u2009=\u2009\u22121.20, 95% CI (\u22121.78, \u2009\u2212\u20090.62), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), HbA1c (MD\u2009=\u2009\u22121.01, 95% CI (\u22121.48, \u2009\u2212\u20090.53), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), and postprandial glycemia (MD\u2009=\u2009\u22121.94, 95% CI (\u22122.99, \u2009\u2212\u20090.90), p\u2009=\u20090.0003). Similarly, for glycemic control, PEX168 monotherapy was superior to placebo (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). No significant effects were noticed in terms of triglycerides, low-density lipoprotein, or high-density lipoprotein (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Body weight was significantly reduced in obese diabetic patients receiving PEX168 compared to the control group (MD\u2009=\u2009\u22125.46, 95% CI (\u22127.90, \u2009\u2212\u20093.01), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) but not in non-obese patients (MD\u2009=\u20090.06, 95% CI (\u22120.47, 0.59), <jats:italic>p<\/jats:italic>\u2009=\u20090.83). People who received PEX168 alone or with metformin showed more common gastrointestinal adverse effects, especially nausea and vomiting (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). PEX168 100, 200, and 300\u00a0ug monotherapy demonstrated comparable safety and diabetes control to metformin, but when combined with metformin, PEX168 100 and 200\u00a0ug showed significant effects on diabetes control; however, only the latter showed a significantly higher incidence of nausea and vomiting (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). PEX168 could be a viable option for treating diabetic patients whose metformin control is inadequate or who cannot tolerate metformin. PEX168 at 100\u00a0ug in combination with metformin was found to be safe and more effective compared to metformin; however, due to the small number of trials included, these findings should be interpreted with caution, and additional trials are required.<\/jats:p>","DOI":"10.1038\/s41598-023-46274-x","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T18:02:28Z","timestamp":1699034548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1038","volume":"13","author":[{"given":"Hazem Mohamed","family":"Salamah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Marey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Tarek","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled Alsayed","family":"Abualkhair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina Essam","family":"Abo-elnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Abdelmonaem","family":"Abdelhaleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abd-Elgawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"46274_CR1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun, H. et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"46274_CR2","unstructured":"World Obesity Day 2022\u2013Accelerating action to stop obesity. https:\/\/www.who.int\/news\/item\/04-03-2022-world-obesity-day-2022-accelerating-action-to-stop-obesity."},{"key":"46274_CR3","unstructured":"Diabetes. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"46274_CR4","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3390\/healthcare10091616","volume":"10","author":"M Yang","year":"2022","unstructured":"Yang, M., Liu, S. & Zhang, C. The related metabolic diseases and treatments of obesity. Healthcare 10, 1616 (2022).","journal-title":"Healthcare"},{"key":"46274_CR5","doi-asserted-by":"publisher","first-page":"101850","DOI":"10.1016\/j.eclinm.2023.101850","volume":"57","author":"B Chong","year":"2023","unstructured":"Chong, B. et al. Trends and predictions of malnutrition and obesity in 204 countries and territories: An analysis of the global burden of disease study 2019. eClinicalMedicine 57, 101850 (2023).","journal-title":"eClinicalMedicine"},{"key":"46274_CR6","unstructured":"Magliano, D. J., Boyko, E. J. & Committee, I. D. A. 10th edition scientific. IDF Diabetes Atlas. 54\u201355 (2021)."},{"key":"46274_CR7","doi-asserted-by":"publisher","first-page":"e006351","DOI":"10.1136\/bmjgh-2021-006351","volume":"6","author":"A Okunogbe","year":"2021","unstructured":"Okunogbe, A., Nugent, R., Spencer, G., Ralston, J. & Wilding, J. Economic impacts of overweight and obesity: Current and future estimates for eight countries. BMJ Glob. Heal. 6, e006351 (2021).","journal-title":"BMJ Glob. Heal."},{"key":"46274_CR8","first-page":"354","volume":"27","author":"J Cawley","year":"2021","unstructured":"Cawley, J. et al. Direct medical costs of obesity in the United States and the most populous states. J. Manag. Care Spec. Pharm. 27, 354\u2013366 (2021).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"46274_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2337\/dci18-0007","volume":"41","author":"W Yang","year":"2018","unstructured":"Yang, W. et al. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 41, 917\u2013928 (2018).","journal-title":"Diabetes Care"},{"key":"46274_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7861\/clinmedicine.19-3-205","volume":"19","author":"A Ruban","year":"2019","unstructured":"Ruban, A., Stoenchev, K., Ashrafian, H. & Teare, J. Current treatments for obesity. Clin. Med. (Northfield. Il) 19, 205\u2013212 (2019).","journal-title":"Clin. Med. (Northfield. Il)"},{"key":"46274_CR11","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/molecules25081987","volume":"25","author":"A Artasensi","year":"2020","unstructured":"Artasensi, A., Pedretti, A., Vistoli, G. & Fumagalli, L. Type 2 diabetes mellitus: A review of multi-target drugs. Molecules 25, 1987 (2020).","journal-title":"Molecules"},{"key":"46274_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00125-019-04985-9","volume":"63","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: A systematic review and meta-analysis of prospective cohort studies. Diabetologia 63, 21\u201333 (2020).","journal-title":"Diabetologia"},{"key":"46274_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ncpendmet0843","volume":"4","author":"JP Crandall","year":"2008","unstructured":"Crandall, J. P. et al. The prevention of type 2 diabetes. Nat. Clin. Pract. Endocrinol. Metab. 4, 382\u2013393 (2008).","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"46274_CR14","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.jand.2017.03.023","volume":"117","author":"J MacLeod","year":"2017","unstructured":"MacLeod, J. et al. Academy of nutrition and dietetics nutrition practice guideline for type 1 and type 2 diabetes in adults: Nutrition intervention evidence reviews and recommendations. J. Acad. Nutr. Diet. 117, 1637\u20131658 (2017).","journal-title":"J. Acad. Nutr. Diet."},{"key":"46274_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-2458-9-88","volume":"9","author":"DP Guh","year":"2009","unstructured":"Guh, D. P. et al. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health 9, 88 (2009).","journal-title":"BMC Public Health"},{"key":"46274_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/DMSO.S67400","volume":"7","author":"A Algoblan","year":"2014","unstructured":"Algoblan, A., Alalfi, M. & Khan, M. Mechanism linking diabetes mellitus and obesity. Diabetes, Metab. Syndr. Obes. Targets Ther. 7, 587. https:\/\/doi.org\/10.2147\/DMSO.S67400 (2014).","journal-title":"Diabetes, Metab. Syndr. Obes. Targets Ther."},{"key":"46274_CR17","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.7861\/clinmed.2021-0370","volume":"21","author":"B Grant","year":"2021","unstructured":"Grant, B., Sandelson, M., Agyemang-Prempeh, B. & Zalin, A. Managing obesity in people with type 2 diabetes. Clin. Med. (Northfield. Il) 21, e327\u2013e231 (2021).","journal-title":"Clin. Med. (Northfield. Il)"},{"key":"46274_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000480525","volume":"10","author":"DR Leitner","year":"2017","unstructured":"Leitner, D. R. et al. Obesity and type 2 diabetes: Two diseases with a need for combined treatment strategies-EASO can lead the way. Obes. Facts 10, 483\u2013492 (2017).","journal-title":"Obes. Facts"},{"key":"46274_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s11883-022-01062-2","volume":"24","author":"MR Pedrosa","year":"2022","unstructured":"Pedrosa, M. R. et al. GLP-1 agonist to treat obesity and prevent cardiovascular disease: What have we achieved so far?. Curr. Atheroscler. Rep. 24, 867\u2013884 (2022).","journal-title":"Curr. Atheroscler. Rep."},{"key":"46274_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck, M. A. & Meier, J. J. Incretin hormones: Their role in health and disease. Diabetes, Obes. Metab. 20, 5\u201321 (2018).","journal-title":"Diabetes, Obes. Metab."},{"key":"46274_CR21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas, A. et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes. Ann. Intern. Med. 173, 278\u2013286 (2020).","journal-title":"Ann. Intern. Med."},{"key":"46274_CR22","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","volume":"372","author":"DJ Drucker","year":"2008","unstructured":"Drucker, D. J. et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet 372, 1240\u20131250 (2008).","journal-title":"Lancet"},{"key":"46274_CR23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.2337\/dc12-0709","volume":"36","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock, J. et al. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes. Diabetes Care 36, 498\u2013504 (2013).","journal-title":"Diabetes Care"},{"key":"46274_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/jcph.386","volume":"55","author":"GR Yang","year":"2015","unstructured":"Yang, G. R., Zhao, X. L., Jin, F., Shi, L. H. & Yang, J. K. Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes. J. Clin. Pharmacol. 55, 152\u2013158 (2015).","journal-title":"J. Clin. Pharmacol."},{"key":"46274_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/1753-0407.12397","volume":"9","author":"X Chen","year":"2017","unstructured":"Chen, X. et al. Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients. J. Diabetes 9, 158\u2013167 (2017).","journal-title":"J. Diabetes"},{"key":"46274_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2023.1106868","volume":"14","author":"H Cai","year":"2023","unstructured":"Cai, H., Chen, Q., Duan, Y., Zhao, Y. & Zhang, X. Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. Front. Endocrinol. (Lausanne) 14, 1\u20139 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"46274_CR27","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1111\/dom.14163","volume":"22","author":"F Gao","year":"2020","unstructured":"Gao, F. et al. Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial. Diabetes, Obes. Metab. 22, 2375\u20132383 (2020).","journal-title":"Diabetes, Obes. Metab."},{"key":"46274_CR28","first-page":"7996","volume":"26","author":"XY Li","year":"2022","unstructured":"Li, X. Y. et al. Effect of polyethylene glycol loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity. Eur. Rev. Med. Pharmacol. Sci. 26, 7996\u20138003 (2022).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"46274_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/dom.14198","volume":"23","author":"Y Shuai","year":"2021","unstructured":"Shuai, Y. et al. Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial. Diabetes. Obes. Metab. 23, 116\u2013124 (2021).","journal-title":"Diabetes. Obes. Metab."},{"key":"46274_CR30","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 18, e1003583 (2021).","journal-title":"PLoS Med."},{"key":"46274_CR31","unstructured":"Higgins, J. P., Savovi\u0107, J., Page, M. J. & Sterne, J. A. C. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) Full Guidance Document. Br. Med. J. 1\u201372 (2019)."},{"key":"46274_CR32","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4, The Cochrane Collaboration, (2020)."},{"key":"46274_CR33","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088\u20131101 (1994).","journal-title":"Biometrics"},{"key":"46274_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Smith, G. D., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629\u2013634 (1997).","journal-title":"BMJ"},{"key":"46274_CR35","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman, M. G. et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA 316, 1289\u20131297 (2016).","journal-title":"JAMA"},{"key":"46274_CR36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s11886-011-0220-3","volume":"13","author":"BG Talayero","year":"2011","unstructured":"Talayero, B. G. & Sacks, F. M. The role of triglycerides in atherosclerosis. Curr. Cardiol. Rep. 13, 544\u2013552 (2011).","journal-title":"Curr. Cardiol. Rep."},{"issue":"Suppl 2","key":"46274_CR37","first-page":"16","volume":"31","author":"J Pedro-Botet","year":"2019","unstructured":"Pedro-Botet, J. & Pint\u00f3, X. LDL-cholesterol: The lower the better. Clin. Investig. Arterioscler. 31(Suppl 2), 16\u201327 (2019).","journal-title":"Clin. Investig. Arterioscler."},{"key":"46274_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12933-014-0171-2","volume":"14","author":"L Blonde","year":"2015","unstructured":"Blonde, L., Pencek, R. & MacConell, L. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: A pooled analysis of patients with type 2 diabetes. Cardiovasc. Diabetol. 14, 12 (2015).","journal-title":"Cardiovasc. Diabetol."},{"key":"46274_CR39","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/dom.13206","volume":"20","author":"SA Jabbour","year":"2018","unstructured":"Jabbour, S. A. et al. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes, Obes. Metab. 20, 1515\u20131519 (2018).","journal-title":"Diabetes, Obes. Metab."},{"key":"46274_CR40","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.2337\/dc11-0447","volume":"34","author":"RH Eckel","year":"2011","unstructured":"Eckel, R. H. et al. Obesity and type 2 diabetes: What can be unified and what needs to be individualized?. Diabetes Care 34, 1424\u20131430 (2011).","journal-title":"Diabetes Care"},{"key":"46274_CR41","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/1753-0407.12883","volume":"11","author":"H Deng","year":"2019","unstructured":"Deng, H. et al. Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-na\u00efve type 2 diabetic patients. J. Diabetes 11, 509\u2013518 (2019).","journal-title":"J. Diabetes"},{"key":"46274_CR42","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.clnu.2018.05.032","volume":"38","author":"E Viguiliouk","year":"2019","unstructured":"Viguiliouk, E. et al. Effect of vegetarian dietary patterns on cardiometabolic risk factors in diabetes: A systematic review and meta-analysis of randomized controlled trials. Clin. Nutr. 38, 1133\u20131145 (2019).","journal-title":"Clin. Nutr."},{"key":"46274_CR43","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc09-S013","volume":"32","author":"American Diabetes Association","year":"2009","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142009. Diabetes Care 32, S13\u2013S61 (2009).","journal-title":"Diabetes Care"},{"key":"46274_CR44","first-page":"462","volume":"72","author":"E Lenters-Westra","year":"2014","unstructured":"Lenters-Westra, E., Schindhelm, R. K., Bilo, H. J. G., Groenier, K. H. & Slingerland, R. J. Differences in interpretation of haemoglobin A1c values among diabetes care professionals. Neth. J. Med. 72, 462\u2013466 (2014).","journal-title":"Neth. J. Med."},{"key":"46274_CR45","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/oby.21358","volume":"23","author":"DA Williamson","year":"2015","unstructured":"Williamson, D. A., Bray, G. A. & Ryan, D. H. Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?. Obesity 23, 2319\u20132320 (2015).","journal-title":"Obesity"},{"key":"46274_CR46","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.eprac.2021.04.008","volume":"27","author":"G Grunberger","year":"2021","unstructured":"Grunberger, G. et al. American association of clinical endocrinology clinical practice guideline: The use of advanced technology in the management of persons with diabetes mellitus. Endocr. Pract. 27, 505\u2013537 (2021).","journal-title":"Endocr. Pract."},{"key":"46274_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/CS-2019-0472","volume":"26","author":"AJ Garber","year":"2020","unstructured":"Garber, A. J. et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm-2020 executive summary. Endocr. Pract. 26, 107\u2013139 (2020).","journal-title":"Endocr. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46274-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46274-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46274-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T19:02:45Z","timestamp":1699038165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46274-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["46274"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-46274-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"14 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19041"}}